Request a Quote |

Cyprotex sign co-marketing agreement with DILIsym Services, Inc.

Cyprotex announce that it has formalised its relationship with DILIsym Services, Inc through an agreement to co-market their joint expertise and capabilities in the area of drug induced liver injury (DILI).

The DILI-sim Initiative is a consortium of pharmaceutical and other life science companies led by DILIsym Services, Inc. The Initiative sponsors the development and application of DILIsym®, a mechanistic model of drug induced liver injury (DILI). Cyprotex, which is a centre of excellence for in vitro toxicology, currently supports the Initiative with mechanistic in vitro data. The data generated feeds directly into the DILIsym® model, which in turn uses Quantitative System Toxicology analysis to evaluate potential in vivo hepatotoxic effects. This combined approach has already been successful in understanding the mechanism of hepatotoxicity of TAK-875, a GPR40 agonist in development for type 2 diabetes, which was withdrawn during Phase 3 trials because of unexplained liver injury.

The co-marketing agreement between Cyprotex and DILIsym Services, Inc will cover:

   • Development of joint marketing material
   • Demonstration of case studies through joint publications, white papers and webinars
   • Joint attendance and sponsoring of conferences and other events
   • Promotion of each other’s products and services

Cyprotex and DILIsym Services, Inc recently presented a case study at SOT in Baltimore, which demonstrated the advantages of the combined approach.

Download the poster





Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below:

Close